Novolene

Semaglutide vs Tirzepatide: Which GLP-1 Is Right for You?

A science-backed comparison of the two most effective FDA-approved medications for chronic weight management.

How Each Medication Works

Semaglutide (GLP-1 only)

Semaglutide is a once-weekly glucagon-like peptideptide-1 (GLP-1) receptor agonist. By mimicking the naturally occurring incretin GLP-1, it slows gastric emptying, reduces appetite centers in the hypothalamus, and enhances insulin sensitivity. The STEP-1 trial (Wilding et al., N Engl J Med 2021) demonstrated an average 14.9 % weight loss at 68 weeks in adults with obesity or overweight.

Tirzepatide (GLP-1 + GIP dual action)

Tirzepatide is the first dual incretin mimetic, simultaneously activating GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. The complementary pathways amplify satiety, improve beta-cell function, and increase energy expenditure. In the SURMOUNT-1 trial (Jastreboff et al., N Engl J Med 2022), participants lost an average 20.9 % of baseline body weight at 72 weeks on the 15 mg dose.

Head-to-Head Effectiveness

Metric Semaglutide (Wegovy) Tirzepatide (Zepbound)
pivotal trial STEP-1 (68 wks) SURMOUNT-1 (72 wks)
Mean weight loss 14.9 % (2.4 mg) 20.9 % (15 mg)
≥ 20 % responders 32 % 57 %
HbA1c reduction (T2DM subset) -1.6 % -2.58 %
Systolic BP reduction -6.2 mmHg -7.4 mmHg

Sources: Wilding JPH, et al. N Engl J Med 2021;384:989; Jastreboff AM, et al. N Engl J Med 2022;387:205-16.

Side-Effect Profile

Semaglutide

  • Nausea 44 % (mild-moderate)
  • Diarrhea 30 %
  • Vomiting 24 %
  • Constipation 24 %
  • Headache 14 %
  • Risk of gallstones (↑ 2-fold)

Most events occur during dose escalation and abate within 4-6 weeks.

Tirzepatide

  • Nausea 29 % (lower incidence vs GLP-1 mono-therapy)
  • Diarrhea 23 %
  • Vomiting 16 %
  • Constipation 17 %
  • Dyspepsia 11 %
  • Injection-site reactions 4 %

GIP co-agonism appears to mitigate GI intolerance compared with GLP-1 alone.

Black-box warning: Both medicines carry thyroid C-cell tumor warnings in rodents; contraindicated in patients with MEN-2 or medullary thyroid carcinoma history.

Monthly Cost Comparison (Novolene Pharmacy)

Semaglutide

$179/mo

  • Includes 4 weekly prefilled pens
  • Free 2-day shipping
  • Provider consult included

Tirzepatide

$299/mo

  • Includes 4 weekly prefilled pens
  • Free 2-day shipping
  • Provider consult included
    • 桔>

Prices reflect cash-pay only; insurance coverage varies. Compounded formulas available in 45 states.

Dosing Schedules

Semaglutide Escalation

  1. Month 1: 0.25 mg weekly
  2. Month 2: 0.5 mg weekly
  3. Month 3: 1 mg weekly
  4. Month 4: 1.7 mg weekly
  5. Maintenance: 2.4 mg weekly

Each dose increase is contingent on tolerability; slower titration reduces GI events.

Tirzepatide Escalated

  1. Month 1: 2.5 mg weekly
  2. Month 2: 5 mg weekly
  3. Month 3: 7.5 mg weekly
  4. Month 4: 10 mg weekly
  5. Optional: 12.5 mg → 15 mg

Dose can be paused or decreased for intolerance; maintenance dose individualized.

Who Should Choose Which?

Consider Semaglutide If You:

  • Want a lower-cost entry point
  • Prefer a medicine with 6+ years post-market safety data
  • Have a history of mild GI sensitivity and desire slower titration
  • Need medication also indicated for cardiovascular risk reduction (FDA 2020)
  • Are currently on metformin and desire additive glycemic benefit

Consider Tirzepatide If You:

  • Seek the highest possible weight-loss efficacy
  • Have class-III obesity (BMI ≥ 40) and need maximal effect
  • Want potentially fewer GI side effects due to dual incretin action
  • Have type 2 diabetes and require superior HBA1c lowering
  • Are comfortable with a newer agent whose long-term data extend to 2027+

Frequently Asked Questions

1. Can I switch between semaglutide and tirzepatide?
Yes. A 4-week washout is recommended to avoid overlapping receptor saturation. Your clinician will restart at the lowest escalation dose.
2. Will I regain weight if I stop?
Both STEP and SURMOUNT extension studies show gradual regain after discontinuation. Lifestyle reinforcement and planned tapering mitigate rebound.
3. Are these covered by insurance?
Commercial plans with obesity riders may cover branded pens. Medicare excludes anti-obesity meds; Novolene cash pricing is offered as an alternative.
4. How do I handle nausea?
Eat smaller, lower-fat meals; remain upright 30 min post-injection; sip ginger tea. If vomiting persists >24 h, hold dose and contact provider.
5. Is either drug safe for pregnancy?
No. Discontinue at least 2 months before planned conception due to long half-life. Safety data in human pregnancy are lacking.
6. Can I drink alcohol?
Limited intake is permissible; however, alcohol augments GI side effects and undermines weight-loss effort. Limit to ≤ 2 drinks/week.

Ready to Personalize Your Plan?

Take the 3-minute clinical questionnaire to see which GLP-1 path aligns with your goals, health profile, and budget.

Start Evaluation